Emergent Biosolutions Operating Margin 2007-2021 | EBS

Current and historical operating margin for Emergent Biosolutions (EBS) over the last 10 years. The current operating profit margin for Emergent Biosolutions as of September 30, 2021 is 17.01%.
Emergent Biosolutions Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $1.65B $0.33B 20.15%
2021-06-30 $1.71B $0.43B 25.10%
2021-03-31 $1.71B $0.54B 31.65%
2020-12-31 $1.56B $0.43B 27.83%
2020-09-30 $1.33B $0.25B 18.98%
2020-06-30 $1.26B $0.26B 20.87%
2020-03-31 $1.11B $0.13B 11.73%
2019-12-31 $1.11B $0.12B 10.40%
2019-09-30 $1.02B $0.05B 4.72%
2019-06-30 $0.88B $-0.00B -0.23%
2019-03-31 $0.86B $0.07B 8.41%
2018-12-31 $0.78B $0.09B 11.37%
2018-09-30 $0.71B $0.13B 18.56%
2018-06-30 $0.68B $0.16B 23.20%
2018-03-31 $0.56B $0.10B 17.79%
2017-12-31 $0.56B $0.13B 22.28%
2017-09-30 $0.52B $0.12B 23.70%
2017-06-30 $0.51B $0.11B 21.44%
2017-03-31 $0.50B $0.10B 19.68%
2016-12-31 $0.49B $0.11B 21.47%
2016-09-30 $0.48B $0.14B 29.08%
2016-06-30 $0.49B $0.17B 33.87%
2016-03-31 $0.53B $0.19B 35.98%
2015-12-31 $0.49B $0.14B 28.83%
2015-09-30 $0.45B $0.13B 29.33%
2015-06-30 $0.43B $0.10B 23.26%
2015-03-31 $0.41B $0.09B 21.01%
2014-12-31 $0.40B $0.09B 22.28%
2014-09-30 $0.40B $0.04B 9.25%
2014-06-30 $0.35B $0.02B 6.84%
2014-03-31 $0.32B $0.03B 9.60%
2013-12-31 $0.31B $0.04B 13.78%
2013-09-30 $0.31B $0.04B 14.24%
2013-06-30 $0.29B $0.04B 12.54%
2013-03-31 $0.28B $0.03B 10.91%
2012-12-31 $0.28B $0.03B 10.64%
2012-09-30 $0.30B $0.05B 17.63%
2012-06-30 $0.29B $0.04B 14.98%
2012-03-31 $0.31B $0.05B 17.70%
2011-12-31 $0.27B $0.03B 11.31%
2011-09-30 $0.27B $0.02B 7.43%
2011-06-30 $0.28B $0.04B 14.08%
2011-03-31 $0.26B $0.04B 13.57%
2010-12-31 $0.29B $0.07B 25.87%
2010-09-30 $0.24B $0.04B 18.14%
2010-06-30 $0.21B $0.02B 8.74%
2010-03-31 $0.22B $0.03B 11.98%
2009-12-31 $0.24B $0.04B 17.02%
2009-09-30 $0.22B $0.04B 17.05%
2009-06-30 $0.23B $0.06B 24.24%
2009-03-31 $0.20B $0.04B 17.91%
2008-12-31 $0.18B $0.03B 16.76%
2008-09-30 $0.23B $0.07B 30.90%
2008-06-30 $0.22B $0.06B 27.73%
2008-03-31 $0.20B $0.05B 24.50%
2007-12-31 $0.18B $0.03B 17.49%
2007-09-30 $0.18B $0.03B 18.33%
2007-06-30 $0.18B $0.04B 21.91%
2007-03-31 $0.17B $0.04B 25.30%
2006-12-31 $0.15B $0.04B 25.66%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.380B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88